Home Featured Page 286

Featured

Latest

Kristen Nash and Erica Siegel on Risk Reduction and Psychedelic Safety

Erica Rex: Scientific Integrity, Psychedelic Research, and the Religious Leader Study

Pα+ Psychedelic Bulletin #203: Norway Considers Funding Off-Label Ketamine for TRD; Longevity Crowd Hypes Psilocybin Study; Will State-Legal Psychedelics Eat Psychedelic Pharma’s Lunch?

Psychedelic Funding Update: Q2 2025

Daniel Pinchbeck – From Cultural Catalyst to Capitalist Co-option: Reflections on Psychedelic Science, AI, and Idealist Monism

PT227- Dr. Anne Wagner – Couples Therapy, MDMA, and MAPS

PT226 – Veronika Gold & Harvey Schwartz from Polaris Insight Center

PT229 – Dr. Matthew Johnson – What is Consciousness?

Light Years – Film Screening and Panel Discussion

PT230 – Penny White of NeonMind Biosciences

DMT for Depression: Paving the Way for New Medicine

Changa vs. DMT: What You Need to Know

Is the DMT Experience a Hallucination?

1...285286287...292 Page 286 of 292

Kristen Nash and Erica Siegel on Risk Reduction and Psychedelic Safety

Erica Rex: Scientific Integrity, Psychedelic Research, and the Religious Leader Study

Pα+ Psychedelic Bulletin #203: Norway Considers Funding Off-Label Ketamine for TRD;...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Kristen Nash and Erica Siegel on Risk Reduction and Psychedelic Safety

Erica Rex: Scientific Integrity, Psychedelic Research, and the Religious Leader Study

Pα+ Psychedelic Bulletin #203: Norway Considers Funding Off-Label Ketamine for TRD; Longevity Crowd Hypes Psilocybin Study; Will State-Legal Psychedelics Eat Psychedelic Pharma’s Lunch?

Psychedelic Funding Update: Q2 2025

Daniel Pinchbeck – From Cultural Catalyst to Capitalist Co-option: Reflections on Psychedelic Science, AI, and Idealist Monism

PT227- Dr. Anne Wagner – Couples Therapy, MDMA, and MAPS

PTSF 42

PT226 – Veronika Gold & Harvey Schwartz from Polaris Insight Center

PTSF 45

PT229 – Dr. Matthew Johnson – What is Consciousness?

Light Years – Film Screening and Panel Discussion

PT230 – Penny White of NeonMind Biosciences

DMT for Depression: Paving the Way for New Medicine

Changa vs. DMT: What You Need to Know

Is the DMT Experience a Hallucination?

EDITOR PICKS

Kristen Nash and Erica Siegel on Risk Reduction and Psychedelic Safety

Erica Rex: Scientific Integrity, Psychedelic Research, and the Religious Leader Study

Pα+ Psychedelic Bulletin #203: Norway Considers Funding Off-Label Ketamine for TRD;...

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY